Search in:

Diabetes, Metabolic Syndrome and Obesity Volume 12, 2019 - Issue

Submit an article Journal homepage

Open access

582

Views

CrossRef citations to date

Altmetric

Review

Canagliflozin review – safety and efficacy profile in patients with T2DM

Haroon Jakher1 Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA, [email protected]Correspondence[email protected]

Tara I Chang2 Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA

Marilyn Tan3 Division of Endocrinology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA

Kenneth W Mahaffey4 Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA

Pages 209-215 | Published online: 01 Feb 2019

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (21)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (21)

Eiji Kutoh, Alexandra N. Kuto, Eri Ozawa, Rumi Kurihara & Midori Akiyama. (2023) Regulation of Adipose Tissue Insulin Resistance and Diabetic Parameters in Drug Naïve Subjects with Type 2 Diabetes Treated with Canagliflozin Monotherapy. Drug Research 73:05, pages 279-288.
Crossref

Marwa Sabaa, Maha H. Sharawy, Mohamed El-Sherbiny, Eman Said, Hatem A. Salem & Tarek M. Ibrahim. (2022) Canagliflozin interrupts mTOR-mediated inflammatory signaling and attenuates DMBA-induced mammary cell carcinoma in rats. Biomedicine & Pharmacotherapy 155, pages 113675.
Crossref

Ryan Kurtz, Andrew Libby, Bryce A. Jones, Komuraiah Myakala, Xiaoxin Wang, Yichien Lee, Grace Knoer, Julia N. Lo Cascio, Michaela McCormack, Grace Nguyen, Elijah N. D. Choos, Olga Rodriguez, Avi Z. Rosenberg, Suman Ranjit, Christopher Albanese, Moshe Levi, Carolyn M. Ecelbarger & Blythe D. Shepard. (2022) Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice. International Journal of Molecular Sciences 23:10, pages 5675.
Crossref

Filip Vymyslický, Tomáš Křížek, Petr Kozlík, Anna Kubíčková, Jakub Heřt & Ewa Bartosińska. (2022) Alternative method for canagliflozin oxidation analysis using an electrochemical flow cell – Comparative study. Journal of Pharmaceutical and Biomedical Analysis 207, pages 114341.
Crossref

Mohamed A. Morsy, Hanaa M. Khalaf, Rehab A. Rifaai, Asmaa M.A. Bayoumi, Esraa M.M.A. Khalifa & Yasmine F. Ibrahim. (2021) Canagliflozin, an SGLT-2 inhibitor, ameliorates acetic acid-induced colitis in rats through targeting glucose metabolism and inhibiting NOX2. Biomedicine & Pharmacotherapy 141, pages 111902.
Crossref

Vaishali Kapila & Joel Topf. (2021) Sodium-Glucose Co-transporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis After Bariatric Surgery: A Case and Literature Review. Cureus.
Crossref

Vivencio Barrios & Carlos Escobar. (2021) Canagliflozin: metabolic, cardiovascular and renal protection. Future Cardiology 17:3, pages 443-458.
Crossref

Prateek Sharma, Sukhbir Singh, Vinay Thakur, Neelam Sharma & Ajmer Singh Grewal. (2021) Novel and emerging therapeutic drug targets for management of type 2 Diabetes Mellitus. Obesity Medicine 23, pages 100329.
Crossref

Lanting Yang, Nico Gabriel, Inmaculada Hernandez, Almut G. Winterstein & Jingchuan Guo. (2021) Using machine learning to identify diabetes patients with canagliflozin prescriptions at high‐risk of lower extremity amputation using real‐world data. Pharmacoepidemiology and Drug Safety 30:5, pages 644-651.
Crossref

Suxiang ChenNabayet SbuhRakesh N. Veedu. (2021) Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes. Nucleic Acid Therapeutics 31:1, pages 39-57.
Crossref

Manfred Schudok, Heiner Glombik & Volker Derdau. (2020) The magic of small structure differences in a sodium‐glucose cotransporter drug discovery project— 14 C‐labelled drug candidates in a key‐differentiating study . Journal of Labelled Compounds and Radiopharmaceuticals 64:2, pages 73-76.
Crossref

Ashish Sarraju, Gabriela Spencer-Bonilla, Fatima Rodriguez & Kenneth W Mahaffey. (2021) Canagliflozin and cardiovascular outcomes in Type 2 diabetes. Future Cardiology 17:1, pages 39-48.
Crossref

Tetiana Titko, Lina Perekhoda, Iryna Drapak & Yevgen Tsapko. (2020) Modern trends in diuretics development. European Journal of Medicinal Chemistry 208, pages 112855.
Crossref

Pietro Delre, Fabiana Caporuscio, Michele Saviano & Giuseppe Felice Mangiatordi. (2020) Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease. Frontiers in Chemistry 8.
Crossref

Miguel Valdés, Fernando Calzada, Jessica Elena Mendieta-Wejebe, Verenice Merlín-Lucas, Claudia Velázquez & Elizabeth Barbosa. (2020) Antihyperglycemic Effects of Annona diversifolia Safford and Its Acyclic Terpenoids: α-Glucosidase and Selective SGLT1 Inhibitiors. Molecules 25:15, pages 3361.
Crossref

Rory J. McCrimmon, Andrei-Mircea Catarig, Juan P. Frias, Nanna L. Lausvig, Carel W. le Roux, Desirée Thielke & Ildiko Lingvay. (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63:3, pages 473-485.
Crossref

Silvia Canivell, Manel Mata-Cases, Bogdan Vlacho, Mònica Gratacòs, Jordi Real, Dídac Mauricio & Josep Franch-Nadal. (2019) How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area. Journal of Diabetes Research 2019, pages 1-9.
Crossref

Ildiko Lingvay, Andrei-Mircea Catarig, Juan P Frias, Harish Kumar, Nanna L Lausvig, Carel W le Roux, Desirée Thielke, Adie Viljoen & Rory J McCrimmon. (2019) Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology 7:11, pages 834-844.
Crossref

Lev M. Berstein. (2019) Is cancer incidence modified by SGLT2 inhibitors?. Diabetes mellitus 22:4, pages 399-402.
Crossref

Teruo Jojima, Sho Wakamatsu, Masato Kase, Toshie Iijima, Yuko Maejima, Kenju Shimomura, Takahiko Kogai, Takuya Tomaru, Isao Usui & Yoshimasa Aso. (2019) The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. International Journal of Molecular Sciences 20:20, pages 5237.
Crossref

Abeer Bishr, Ahmed M. Atwa, Mostafa E. El-Naggar & Mahmoud Nour El-Din. (2021) Canagliflozin Promotes Mitochondrial Biogenesis in Glycerol-Induced Acute Kidney Injury by Activating the AMPK/SIRT1/FOXO-3a/ PGC-1α and Nrf2/HO-1 Trajectories. SSRN Electronic Journal.
Crossref

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Canagliflozin review – safety and efficacy profile in patients with T2DM

Articles from other publishers (21)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Canagliflozin review – safety and efficacy profile in patients with T2DM

Citations (21)

Articles from other publishers (21)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date